321 related articles for article (PubMed ID: 12461829)
1. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
Zuurmond WW; Meert TF; Noorduin H
Acta Anaesthesiol Belg; 2002; 53(3):193-201. PubMed ID: 12461829
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
Koltzenburg M; Pokorny R; Gasser UE; Richarz U
Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
[TBL] [Abstract][Full Text] [Related]
5. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
Kress HG
Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine: considerations for pain management.
Johnson RE; Fudala PJ; Payne R
J Pain Symptom Manage; 2005 Mar; 29(3):297-326. PubMed ID: 15781180
[TBL] [Abstract][Full Text] [Related]
7. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
8. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
10. Current knowledge of buprenorphine and its unique pharmacological profile.
Pergolizzi J; Aloisi AM; Dahan A; Filitz J; Langford R; Likar R; Mercadante S; Morlion B; Raffa RB; Sabatowski R; Sacerdote P; Torres LM; Weinbroum AA
Pain Pract; 2010; 10(5):428-50. PubMed ID: 20492579
[TBL] [Abstract][Full Text] [Related]
11. Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine.
Galici R; McMahon LR; France CP
Pharmacol Biochem Behav; 2005 Jul; 81(3):626-34. PubMed ID: 15946731
[TBL] [Abstract][Full Text] [Related]
12. The potential for mu-opioid receptor agonists to be anti-emetic in humans: a review of clinical data.
Johnston KD
Acta Anaesthesiol Scand; 2010 Feb; 54(2):132-40. PubMed ID: 19817719
[TBL] [Abstract][Full Text] [Related]
13. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.
Davis MP
J Support Oncol; 2012; 10(6):209-19. PubMed ID: 22809652
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
Clark MJ; Furman CA; Gilson TD; Traynor JR
J Pharmacol Exp Ther; 2006 May; 317(2):858-64. PubMed ID: 16436499
[TBL] [Abstract][Full Text] [Related]
16. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.
Koppert W; Ihmsen H; Körber N; Wehrfritz A; Sittl R; Schmelz M; Schüttler J
Pain; 2005 Nov; 118(1-2):15-22. PubMed ID: 16154698
[TBL] [Abstract][Full Text] [Related]
17. Opioid pharmacology.
Trescot AM; Datta S; Lee M; Hansen H
Pain Physician; 2008 Mar; 11(2 Suppl):S133-53. PubMed ID: 18443637
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine TTS for children--a review of the drug's clinical pharmacology.
Michel E; Anderson BJ; Zernikow B
Paediatr Anaesth; 2011 Mar; 21(3):280-90. PubMed ID: 21091589
[TBL] [Abstract][Full Text] [Related]
19. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Kuo A; Wyse BD; Meutermans W; Smith MT
Br J Pharmacol; 2015 Jan; 172(2):532-48. PubMed ID: 24641546
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.
Yassen A; Olofsen E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2005 Jun; 313(3):1136-49. PubMed ID: 15701707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
